Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a significant growth in short interest in May. As of May 29th, there was short interest totaling 315,885 shares, a growth of 5,048.9% from the May 14th total of 6,135 shares. Currently, 1.9% of the company’s stock are sold short. Based on an average daily trading volume, of 1,158,189 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Genenta Science Price Performance

NASDAQ GNTA opened at $1.60 on Wednesday. The firm’s fifty day simple moving average is $0.85 and its two-hundred day simple moving average is $1.10. The company has a quick ratio of 14.16, a current ratio of 14.16 and a debt-to-equity ratio of 0.35. Genenta Science has a 12-month low of $0.55 and a 12-month high of $10.00.

Genenta Science (NASDAQ:GNTA) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.28.

Hedge Funds Weigh In On Genenta Science

Several hedge funds have recently made changes to their positions in GNTA. Eurizon Capital SGR S.p.A. acquired a new position in shares of Genenta Science in the 4th quarter valued at $536,000. Ghisallo Capital Management LLC acquired a new position in shares of Genenta Science in the 4th quarter valued at $482,000. Weiss Asset Management LP acquired a new position in shares of Genenta Science in the 4th quarter valued at $480,000. Norges Bank purchased a new stake in Genenta Science in the fourth quarter valued at $337,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Genenta Science in the fourth quarter valued at $328,000. 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.